id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-D-1118-0007,FDA,FDA-2020-D-1118,"Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH)
Guidance for Industry and Food and Drug Administration Staff",Other,Guidance,2021-12-27T05:00:00Z,2021,12,2021-12-27T05:00:00Z,,2024-11-12T23:35:29Z,,1,0,0900006484efdb6c
FDA-2020-D-1118-0006,FDA,FDA-2020-D-1118,"Non-Clinical and Clinical Investigation
of Devices Used for the Treatment of
Benign Prostatic Hyperplasia;
Guidance for Industry and Food and
Drug Administration Staff; Availability",Notice,Notice of Availability,2021-12-27T05:00:00Z,2021,12,2021-12-27T05:00:00Z,,2021-12-27T14:34:07Z,2021-27919,0,0,0900006484efd897
FDA-2020-D-1118-0005,FDA,FDA-2020-D-1118,Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH); Guidance for Industry and Food and Drug Administration Staff,Other,Guidance,2021-12-23T05:00:00Z,2021,12,2021-12-23T05:00:00Z,,2021-12-27T16:53:22Z,,0,0,0900006484ee91b6
FDA-2020-D-1118-0002,FDA,FDA-2020-D-1118,Select Updates for Guidance for the Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH) Draft Guidance  for Industry and Food and Drug Administration Staff,Other,Guidance,2020-07-14T04:00:00Z,2020,7,2020-07-14T04:00:00Z,,2021-12-27T16:53:05Z,,0,0,090000648474cebf
FDA-2020-D-1118-0001,FDA,FDA-2020-D-1118,"Select Updates for Guidance for the Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia; Draft Guidance for Industry and Food and
Drug Administration Staff; Availability",Notice,Notice of Availability,2020-07-14T04:00:00Z,2020,7,2020-07-14T04:00:00Z,2020-09-15T03:59:59Z,2020-09-15T01:02:30Z,2020-15089,0,0,0900006484752e7a